The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Iovance Biotherapeutics P/E ratio is -5.26. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Iovance Biotherapeutics’s P/E ratio

**Contents**hide

## What is Iovance Biotherapeutics P/E Ratio?

Iovance Biotherapeutics’ P/E ratio is -5.26, which represents a 57.2% increase over the same period last year. their average P/E ratio is -8.67 and their 5-year average is -11.22.

## What is Iovance Biotherapeutics Net EPS?

Iovance Biotherapeutics’ net earnings for the most recent quarter were -2.28 US dollars, which represents a 19.37% decrease from the same period last year.

## Who are Iovance Biotherapeutics Competitors?

Based on Jika.io AI model, bluebird bio, BioXcel Therapeutics, Krystal Biotech, Seres Therapeutics, Mersana Therapeutics, Nurix Therapeutics, Revance Therapeutics, Y-mAbs Therapeutics are considered to be Iovance Biotherapeutics’s competitors because the companies operate within the same industry as Iovance Biotherapeutics and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Iovance Biotherapeutics.

## Who is Iovance Biotherapeutics’s Biggest competitor?

The biggest competitor of Iovance Biotherapeutics is Bluebird Bio, based on the Jika.io AI model. it has a similar market capitalization to Iovance Biotherapeutics within the industry, it dominates a similar share of the market as Iovance Biotherapeutics, and it provides and markets very similar services.

## What industry is Iovance Biotherapeutics in?

Iovance Biotherapeutics is part of the biotechnology and healthcare industry.

## Iovance Biotherapeutics vs bluebird bio

Market Cap: Iovance Biotherapeutics’s Market Cap of 1884444288 is higher than bluebird bio Market Cap of 344406816.

Average Volume: Iovance Biotherapeutics’s Average Volume of 5.025M is lower than bluebird bio Average Volume of 6.683M.

Beta: Iovance Biotherapeutics’s Beta of 0.91 is lower than bluebird bio Beta of 1.69.

Revenue: Iovance Biotherapeutics’s Revenue of 0.0 is lower than bluebird bio Revenue of 3.662M.

Net Income: Iovance Biotherapeutics’s Net Income of -342.252M is lower than bluebird bio Net Income of -819.378M.

Gross Profit: Iovance Biotherapeutics’s Gross Profit of 0.0 is higher than bluebird bio Gross Profit of -35.195M.

Ebitda: Iovance Biotherapeutics’s Ebitda of -342.703M is lower than bluebird bio Ebitda of -798.592M.

P/E Ratio: Iovance Biotherapeutics’s P/E Ratio of -5.26 is higher than bluebird bio P/E Ratio of -0.48.

P/B Ratio: Iovance Biotherapeutics’s P/B Ratio of 3.41 is higher than bluebird bio P/B Ratio of 1.35.

P/FCF Ratio: Iovance Biotherapeutics’s P/FCF Ratio of -6.78 is higher than bluebird bio P/FCF Ratio of -0.62.

ROE: Iovance Biotherapeutics’s ROE of -0.55 is lower than bluebird bio ROE of -1.18.

ROA: Iovance Biotherapeutics’s ROA of -0.51 is lower than bluebird bio ROA of -1.5.

Return On Capital Employed: Iovance Biotherapeutics’s Return On Capital Employed of -0.57 is lower than bluebird bio Return On Capital Employed of -1.38.

Assets (Total): Iovance Biotherapeutics’s Assets (Total) of 777.333M is higher than bluebird bio Assets (Total) of 593.795M.

Debt (Total): Iovance Biotherapeutics’s Debt (Total) of 141.062M is lower than bluebird bio Debt (Total) of 89.584M.

Shareholders Equity: Iovance Biotherapeutics’s Shareholders Equity of 621.659M is higher than bluebird bio Shareholders Equity of 374.277M.

## Iovance Biotherapeutics vs BioXcel Therapeutics

Market Cap: Iovance Biotherapeutics’s Market Cap of 1884444288 is higher than BioXcel Therapeutics Market Cap of 443563840.

Average Volume: Iovance Biotherapeutics’s Average Volume of 5.025M is lower than BioXcel Therapeutics Average Volume of 676381.0.

Beta: Iovance Biotherapeutics’s Beta of 0.91 is lower than BioXcel Therapeutics Beta of 1.3.

Revenue: Iovance Biotherapeutics’s Revenue of 0.0 is lower than BioXcel Therapeutics Revenue of 0.0.

Net Income: Iovance Biotherapeutics’s Net Income of -342.252M is lower than BioXcel Therapeutics Net Income of 0.0.

Gross Profit: Iovance Biotherapeutics’s Gross Profit of 0.0 is lower than BioXcel Therapeutics Gross Profit of 0.0.

Ebitda: Iovance Biotherapeutics’s Ebitda of -342.703M is higher than BioXcel Therapeutics Ebitda of -106.935M.

P/E Ratio: Iovance Biotherapeutics’s P/E Ratio of -5.26 is higher than BioXcel Therapeutics P/E Ratio of -5.16.

P/B Ratio: Iovance Biotherapeutics’s P/B Ratio of 3.41 is higher than BioXcel Therapeutics P/B Ratio of 2.29.

P/FCF Ratio: Iovance Biotherapeutics’s P/FCF Ratio of -6.78 is higher than BioXcel Therapeutics P/FCF Ratio of -5.89.

ROE: Iovance Biotherapeutics’s ROE of -0.55 is higher than BioXcel Therapeutics ROE of -0.37.

ROA: Iovance Biotherapeutics’s ROA of -0.51 is higher than BioXcel Therapeutics ROA of -0.41.

Return On Capital Employed: Iovance Biotherapeutics’s Return On Capital Employed of -0.57 is lower than BioXcel Therapeutics Return On Capital Employed of -0.57.

Assets (Total): Iovance Biotherapeutics’s Assets (Total) of 777.333M is higher than BioXcel Therapeutics Assets (Total) of 239.439M.

Debt (Total): Iovance Biotherapeutics’s Debt (Total) of 141.062M is higher than BioXcel Therapeutics Debt (Total) of 0.0.

Shareholders Equity: Iovance Biotherapeutics’s Shareholders Equity of 621.659M is higher than BioXcel Therapeutics Shareholders Equity of 221.667M.

## Iovance Biotherapeutics vs Krystal Biotech

Market Cap: Iovance Biotherapeutics’s Market Cap of 1884444288 is lower than Krystal Biotech Market Cap of 1915711104.

Average Volume: Iovance Biotherapeutics’s Average Volume of 5.025M is higher than Krystal Biotech Average Volume of 182158.0.

Beta: Iovance Biotherapeutics’s Beta of 0.91 is lower than Krystal Biotech Beta of 0.99.

Revenue: Iovance Biotherapeutics’s Revenue of 0.0 is lower than Krystal Biotech Revenue of 0.0.

Net Income: Iovance Biotherapeutics’s Net Income of -342.252M is lower than Krystal Biotech Net Income of -69.57M.

Gross Profit: Iovance Biotherapeutics’s Gross Profit of 0.0 is lower than Krystal Biotech Gross Profit of 0.0.

Ebitda: Iovance Biotherapeutics’s Ebitda of -342.703M is lower than Krystal Biotech Ebitda of -65.309M.

P/E Ratio: Iovance Biotherapeutics’s P/E Ratio of -5.26 is higher than Krystal Biotech P/E Ratio of -18.09.

P/B Ratio: Iovance Biotherapeutics’s P/B Ratio of 3.41 is lower than Krystal Biotech P/B Ratio of 3.42.

P/FCF Ratio: Iovance Biotherapeutics’s P/FCF Ratio of -6.78 is higher than Krystal Biotech P/FCF Ratio of -13.72.

ROE: Iovance Biotherapeutics’s ROE of -0.55 is higher than Krystal Biotech ROE of -0.21.

ROA: Iovance Biotherapeutics’s ROA of -0.51 is higher than Krystal Biotech ROA of -0.17.

Return On Capital Employed: Iovance Biotherapeutics’s Return On Capital Employed of -0.57 is higher than Krystal Biotech Return On Capital Employed of -0.19.

Assets (Total): Iovance Biotherapeutics’s Assets (Total) of 777.333M is higher than Krystal Biotech Assets (Total) of 626.295M.

Debt (Total): Iovance Biotherapeutics’s Debt (Total) of 141.062M is lower than Krystal Biotech Debt (Total) of 8.024M.

Shareholders Equity: Iovance Biotherapeutics’s Shareholders Equity of 621.659M is higher than Krystal Biotech Shareholders Equity of 593.576M.

## Iovance Biotherapeutics vs Seres Therapeutics

Market Cap: Iovance Biotherapeutics’s Market Cap of 1884444288 is higher than Seres Therapeutics Market Cap of 345982848.

Average Volume: Iovance Biotherapeutics’s Average Volume of 5.025M is higher than Seres Therapeutics Average Volume of 1.072M.

Beta: Iovance Biotherapeutics’s Beta of 0.91 is lower than Seres Therapeutics Beta of 3.44.

Revenue: Iovance Biotherapeutics’s Revenue of 0.0 is lower than Seres Therapeutics Revenue of 144.927M.

Net Income: Iovance Biotherapeutics’s Net Income of -342.252M is lower than Seres Therapeutics Net Income of -65.578M.

Gross Profit: Iovance Biotherapeutics’s Gross Profit of 0.0 is lower than Seres Therapeutics Gross Profit of 144.927M.

Ebitda: Iovance Biotherapeutics’s Ebitda of -342.703M is lower than Seres Therapeutics Ebitda of -62.541M.

P/E Ratio: Iovance Biotherapeutics’s P/E Ratio of -5.26 is higher than Seres Therapeutics P/E Ratio of -3.98.

P/B Ratio: Iovance Biotherapeutics’s P/B Ratio of 3.41 is lower than Seres Therapeutics P/B Ratio of 4.27.

P/FCF Ratio: Iovance Biotherapeutics’s P/FCF Ratio of -6.78 is lower than Seres Therapeutics P/FCF Ratio of -8.34.

ROE: Iovance Biotherapeutics’s ROE of -0.55 is lower than Seres Therapeutics ROE of -0.71.

ROA: Iovance Biotherapeutics’s ROA of -0.51 is higher than Seres Therapeutics ROA of -0.27.

Return On Capital Employed: Iovance Biotherapeutics’s Return On Capital Employed of -0.57 is higher than Seres Therapeutics Return On Capital Employed of -0.36.

Assets (Total): Iovance Biotherapeutics’s Assets (Total) of 777.333M is higher than Seres Therapeutics Assets (Total) of 354.859M.

Debt (Total): Iovance Biotherapeutics’s Debt (Total) of 141.062M is lower than Seres Therapeutics Debt (Total) of 49.136M.

Shareholders Equity: Iovance Biotherapeutics’s Shareholders Equity of 621.659M is higher than Seres Therapeutics Shareholders Equity of 131.507M.

## About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of the immune system to eradicate cancer cells. it has six ongoing phase 2 clinical studies, including C-144-01, its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, its lead product candidate, lifileucel, for recurrent, metastatic or persistent cervical cancer; and C-145-03, its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l’Université de Montréal; Cellectis S.A.; and Novartis Pharma AG. the company was previously known as Lion Biotechnologies, Inc., and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and has its headquarters in San Carlos, California.